美罗培南与丙戊酸药物相互作用的PBPK模型评估
本研究建立美罗培南与丙戊酸的生理药代动力学(PBPK)模型,定量探究两者药物相互作用(DDI)机制。模拟显示合用美罗培南时丙戊酸葡萄糖醛酸苷水解产物血浆浓度降至63%,丙戊酸总血浆浓度从53.61 mg/L降至45.42 mg/L,单抑制水解不足以快速大幅降低丙戊酸浓度。结论提示DDI为多因素综合结果,建议间隔4-6小时给药或优选丙戊酸静脉溶液。
要点
- 合用美罗培南时丙戊酸葡萄糖醛酸苷水解产物浓度降至63%。
- 丙戊酸总血浆浓度从53.61 mg/L降至45.42 mg/L。
- 建议美罗培南注射剂与丙戊酸速释片间隔4-6小时给药。
核心结论
- 美罗培南与丙戊酸的DDI可能是多因素综合结果,单抑制VPAG水解不能导致丙戊酸血浆浓度快速大幅下降。
研究设计与样本
- 建立美罗培南与丙戊酸的PBPK模型并经验证,用于定量研究潜在DDI,并评估APEH基因多态性的影响。
主要发现
- 模拟中合用美罗培南时VPAG水解产物血浆浓度降至63%。
- 碳青霉烯使用前丙戊酸总血浆浓度为53.61 mg/L,使用期间为45.42 mg/L。
- 参数敏感性分析显示吸收变化对丙戊酸Cmax重要,而AUC更易受消除变化影响。
- APEH活性降低对丙戊酸血浆药代动力学影响很小。
关键数值与推荐
- 临床必需合用时,建议美罗培南注射剂与丙戊酸速释片间隔4-6小时给药,或优选丙戊酸静脉溶液。
临床怎么用
- 临床需合用美罗培南与丙戊酸时,可采取间隔4-6小时给药或改用丙戊酸静脉溶液以降低DDI风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The present study aimed to quantitatively investigate the potential drug-drug interaction (DDI) mechanism between meropenem (MEPM) and valproic acid (VPA). METHODS: In the present study, we firstly developed a physiologically based pharmacokinetic (PBPK) model of MEPM and VPA. The verified PBPK model was then used to quantitatively investigate the potential DDI between MEPM and VPA. The effect of genetic polymorphisms of acylpeptide hydrolase (APEH) on DDI was also evaluated. RESULTS: In our simulation, the plasma concentration of hydrolysate of VPAG decreased to 63% when combined with MEPM. Total plasma concentration of VPA before carbapenem use was 53.61 mg/L, whereas it was 45.42 mg/L during carbapenem use. The inhibition of hydrolysis of VPAG by MEPM alone could not result in a rapid and substantial decrease in the plasma concentration of VPA. Parameter sensitivity analysis showed that the changes of absorption played an important role in the maximum plasma concentration (Cmax) of VPA, whereas area under the plasma concentration-time profile (AUC) was more susceptible to elimination changes. In addition, a decrease in APEH activity had little impact on the plasma pharmacokinetics of VPA. CONCLUSIONS: The DDI between MEPM and VPA might be a comprehensive result of multiple factors. On the basis of our simulation, interval medication of MEPM injection and VPA immediate release tablet at 4-6 h timed interval was recommended, or intravenous administration of VPA solution was preferred when combination regimen was necessary in a clinical setting.
引用
- Liu H, Yu Y, Qin Y, et al. PBPK modelling for the evaluation of drug-drug interaction between meropenem and valproic acid. Br J Clin Pharmacol. 2024. PMID: 39578702. doi:10.1111/bcp.16350
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。